20 July 2021 - Regeneron Pharmaceuticals today announced that Japan's Ministry of Health, Labour and Welfare has approved Regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19.
This marks the first time the antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in other countries, has received a full approval to treat COVID-19.
Emergency or temporary pandemic use authorisations are currently in place in more than 20 countries, including in the U.S., European Union, India, Switzerland and Canada.